Report by Lord Mandelson calls for more focus on critical technologies as part of wider industrial strategy
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
High rates of vomiting among those who took strong doses in trials have unsettled investors
Company’s chief oncology officer says reforms risk discouraging treatments for paediatric and rare conditions
Danish pharma company also unveils early data for closely watched oral pill to tackle weight loss
Failure to reach statistical significance sets back effort to build oncology portfolio
Medical breakthroughs come with spiralling price tag, leaving policymakers with tough decisions
A three-part FT series looks at how an influx of money is changing prospects for patients but creating new challenges for healthcare systems
Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology
More trials urged as part of effort to slow cognitive declines with existing medicines
Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
The first in an FT series looking at the new energy behind the fight for cancer cures
Pharma groups are finally turning their research focus to a huge unmet need
Easing the squeeze on the share of health spending that goes on medicine may alleviate pain
Doblin leaves Lykos Therapeutics board after work on treatment for PTSD suffered setback from FDA ruling
The Food and Drug Administration’s rejection of MDMA-assisted therapy is a missed opportunity
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Drugmaker has benefited from its bet on developing a portfolio of cancer drugs
Drugmakers will receive flat fees for new medicines in push to avoid encouraging overuse
Pharma companies are moving up the supply chain to secure radioactive materials for a new form of drugs
Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
For years, the process for developing and testing new drugs has focused disproportionately on male bodies — to the detriment of female patients
Swiss drugmaker unveils promising data for obesity drug
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
